# Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors

> **NCT01337505** · PHASE1 · COMPLETED · sponsor: **ImmunityBio, Inc.** · enrollment: 24 (actual)

## Conditions studied

- Malignant Solid Tumour

## Interventions

- **DRUG:** INNO-206

## Key facts

- **NCT ID:** NCT01337505
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2012-09
- **Final completion:** 2012-12
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2022-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01337505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01337505, "Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01337505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*